Sanofi makes case for why its first cancer drug in a decade can take on Darzalex
The French pharma lays out its strategy for re-entering oncology, bolstered by new Sarclisa data
Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for the CD38 inhibitor.
On Tuesday, Sanofi (Euronext:SAN; NASDAQ:SNY) shared data from the Phase III IKEMA study in advance of the European Hematology Association Virtual Congress showing efficacy rates for Sarclisa isatuximab in a new combination with carfilzomib and dexamethasone that point to a potential advantage over other CD38 inhibitors.
In the second-line or greater setting in